OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
March 28, 2018 01:01 ET
|
Ablynx NV
GEREGLEMENTEERDE INFORMATIE GENT, België, 28 maart 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 28, 2018 01:01 ET
|
Ablynx NV
REGULATED INFORMATION GHENT, Belgium, 28 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the...
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
March 26, 2018 01:11 ET
|
Ablynx NV
GEREGLEMENTEERDE INFORMATIE GENT, België, 26 maart 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 26, 2018 01:11 ET
|
Ablynx NV
REGULATED INFORMATION GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the...
ABLYNX DEELT TOPLINE RESULTATEN MEE VAN DE FASE II STUDIE MET VOBARILIZUMAB IN PATIENTEN MET SYSTEMISCHE LUPUS ERYTHEMATODES
March 26, 2018 01:01 ET
|
Ablynx NV
GEREGLEMENTEERDE INFORMATIE - VOORWETENSCHAP GENT, België, 26 maart 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend dat in de Fase II dosis-bepalende studie met...
ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
March 26, 2018 01:01 ET
|
Ablynx NV
REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the Phase II dose-ranging study of vobarilizumab, the...
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
March 22, 2018 02:01 ET
|
Ablynx NV
GEREGLEMENTEERDE INFORMATIE GENT, België, 22 maart 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 22, 2018 02:01 ET
|
Ablynx NV
REGULATED INFORMATION GHENT, Belgium, 22 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the...
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
March 21, 2018 02:01 ET
|
Ablynx NV
GEREGLEMENTEERDE INFORMATIE GENT, België, 21 maart 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
March 21, 2018 02:01 ET
|
Ablynx NV
REGULATED INFORMATION GHENT, Belgium, 21 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the...